These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11397656)

  • 21. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 23. [Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
    Gutiérrez F; Moltó J; Escolano C; Mora A; Pasquau F; Gregori J; Nogueira E
    Med Clin (Barc); 2000 Oct; 115(11):401-4. PubMed ID: 11093841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
    Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
    AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypic testing for human immunodeficiency virus type 1 drug resistance.
    Shafer RW
    Clin Microbiol Rev; 2002 Apr; 15(2):247-77. PubMed ID: 11932232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
    Hirsch MS; Conway B; D'Aquila RT; Johnson VA; Brun-Vézinet F; Clotet B; Demeter LM; Hammer SM; Jacobsen DM; Kuritzkes DR; Loveday C; Mellors JW; Vella S; Richman DD
    JAMA; 1998 Jun; 279(24):1984-91. PubMed ID: 9643863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs.
    Dunne AL; Mitchell FM; Coberly SK; Hellmann NS; Hoy J; Mijch A; Petropoulos CJ; Mills J; Crowe SM
    AIDS; 2001 Aug; 15(12):1471-5. PubMed ID: 11504978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities.
    Sullivan PS; Buskin SE; Turner JH; Cheingsong R; Saekhou A; Kalish ML; Jones JL; Respess R; Kovacs A; Heneine W
    Int J STD AIDS; 2002 Aug; 13(8):554-8. PubMed ID: 12194739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance against reverse transcriptase inhibitors.
    O'Brien WA
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.
    Gallego O; Ruiz L; Vallejo A; Ferrer E; Rubio A; Clotet B; Leal M; Soriano V;
    AIDS; 2001 Sep; 15(14):1894-6. PubMed ID: 11579258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting HIV: antiretroviral therapy and development of drug resistance.
    Menéndez-Arias L
    Trends Pharmacol Sci; 2002 Aug; 23(8):381-8. PubMed ID: 12377580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
    Brandin E; Lindborg L; Gyllensten K; Broström C; Hagberg L; Gisslen M; Tuvesson B; Blaxhult A; Albert J
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):543-50. PubMed ID: 12908931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
    Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
    J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.
    Weber J; Vazquez AC; Winner D; Rose JD; Wylie D; Rhea AM; Henry K; Pappas J; Wright A; Mohamed N; Gibson R; Rodriguez B; Soriano V; King K; Arts EJ; Olivo PD; Quiñones-Mateu ME
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3729-42. PubMed ID: 21628544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.